Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human fibrinogen in congenital fibrinogen deficiency
CTR20240750Phase 3Completed
- Sponsor
- Danxia Biological Pharmaceutical
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Fibrinogen human in fibrinogen deficiency, congenital afibrinogenemia, congenital hypofibrinogenemia, Congenital dysfibrinogenemia (CD), Acquired fibrinogenopenia, sponsored by Danxia Biological Pharmaceutical. Started Mar 2024; status: completed.
02
Drugs
Fibrinogen human
03
Conditions
fibrinogen deficiencycongenital afibrinogenemiacongenital hypofibrinogenemiaCongenital dysfibrinogenemia (CD)Acquired fibrinogenopenia
Beyond the preview
Go deeper on CTR20240750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240750.